Benjamin F. Edwards & Company Inc. increased its stake in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 54.8% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,990 shares of the medical equipment provider’s stock after acquiring an additional 1,058 shares during the period. Benjamin F. Edwards & Company Inc.’s holdings in Zimmer Biomet were worth $361,000 as of its most recent SEC filing.
A number of other large investors also recently made changes to their positions in the stock. Creative Planning grew its position in Zimmer Biomet by 2.9% in the fourth quarter. Creative Planning now owns 15,765 shares of the medical equipment provider’s stock worth $1,902,000 after acquiring an additional 443 shares in the last quarter. Stralem & Co. Inc. grew its position in Zimmer Biomet by 23.9% in the fourth quarter. Stralem & Co. Inc. now owns 8,300 shares of the medical equipment provider’s stock worth $1,002,000 after acquiring an additional 1,600 shares in the last quarter. National Pension Service grew its position in Zimmer Biomet by 6.3% in the fourth quarter. National Pension Service now owns 198,495 shares of the medical equipment provider’s stock worth $23,952,000 after acquiring an additional 11,695 shares in the last quarter. Bank of Montreal Can grew its position in Zimmer Biomet by 7.7% in the fourth quarter. Bank of Montreal Can now owns 229,641 shares of the medical equipment provider’s stock worth $27,711,000 after acquiring an additional 16,421 shares in the last quarter. Finally, Starfire Investment Advisers Inc. purchased a new position in Zimmer Biomet in the fourth quarter worth $458,000. Institutional investors own 86.36% of the company’s stock.
ZBH has been the subject of several analyst reports. Goldman Sachs Group upgraded shares of Zimmer Biomet from a “sell” rating to a “neutral” rating and set a $125.00 price target for the company in a research report on Tuesday, December 19th. Stifel Nicolaus upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating and upped their price target for the company from $120.00 to $168.00 in a research report on Wednesday, January 31st. Canaccord Genuity restated a “hold” rating and set a $132.00 price target on shares of Zimmer Biomet in a research report on Friday, January 5th. Robert W. Baird restated a “buy” rating on shares of Zimmer Biomet in a research report on Wednesday, January 31st. Finally, BMO Capital Markets restated a “buy” rating and set a $142.00 price target on shares of Zimmer Biomet in a research report on Tuesday, December 12th. Two analysts have rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $141.67.
Zimmer Biomet Holdings Inc (ZBH) traded up $0.13 during trading on Monday, hitting $116.52. 1,467,080 shares of the stock were exchanged, compared to its average volume of 1,567,795. The company has a current ratio of 1.52, a quick ratio of 0.83 and a debt-to-equity ratio of 0.76. The stock has a market capitalization of $23,670.00, a price-to-earnings ratio of 12.92, a P/E/G ratio of 2.04 and a beta of 1.08. Zimmer Biomet Holdings Inc has a one year low of $108.03 and a one year high of $133.49.
Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $2.10. Zimmer Biomet had a net margin of 23.51% and a return on equity of 15.45%. The company had revenue of $2.07 billion during the quarter, compared to analyst estimates of $2.03 billion. During the same period in the prior year, the business posted $2.14 earnings per share. Zimmer Biomet’s revenue for the quarter was up 3.0% on a year-over-year basis. sell-side analysts anticipate that Zimmer Biomet Holdings Inc will post 7.82 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Monday, January 29th. Investors of record on Friday, December 29th were paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.82%. The ex-dividend date was Thursday, December 28th. Zimmer Biomet’s payout ratio is currently 10.64%.
TRADEMARK VIOLATION WARNING: “Benjamin F. Edwards & Company Inc. Has $361,000 Holdings in Zimmer Biomet Holdings Inc (ZBH)” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/12/zimmer-biomet-holdings-inc-zbh-shares-bought-by-benjamin-f-edwards-company-inc.html.
Zimmer Biomet Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.